Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer [0.03%]
细胞外基质硬度：肿瘤进展中的机制及其在癌症治疗中的潜力
Meiling Zhang,Bin Zhang
Meiling Zhang
Tumor microenvironment (TME) is a complex ecosystem composed of both cellular and non-cellular components that surround tumor tissue. The extracellular matrix (ECM) is a key component of the TME, performing multiple essential functions by p...
NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors [0.03%]
NKG2D/CD28嵌合受体增强CAR-T细胞对实体瘤和血液系统肿瘤的细胞毒性和持久性
Xia Teng,Shance Li,Chaoting Zhang et al.
Xia Teng et al.
Background: CAR-T cell therapy faces challenges in solid tumor treatment and hematologic malignancy relapse, among which the limited persistence of CAR-T cells and target antigen downregulation are prominent factors. Ther...
Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways [0.03%]
通过增强代谢途径工程化IL-21可增强CAR-NK细胞特异性杀伤CD19阳性B淋巴瘤细胞活性
Bailin He,Hong Chen,Jiaxu Wu et al.
Bailin He et al.
Background: NK cells engineered to express interleukin-15 (IL-15) and a CD19-targeted chimeric antigen receptor (CAR) have been used to treat patients with relapsed and/or refractory B cell malignances, demonstrating enco...
Correction: Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain [0.03%]
关于PD1胞外区修饰的嵌合抗原受体T细胞靶向性和杀伤活性的校正文章
Ang Zhang,Shenyu Wang,Yao Sun et al.
Ang Zhang et al.
Published Erratum
Experimental hematology & oncology. 2025 Apr 2;14(1):50. DOI:10.1186/s40164-025-00645-4 2025
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond [0.03%]
肿瘤微环境中的RNA修饰：对癌症免疫循环及其以外领域的洞察
You-Peng Ding,Cui-Cui Liu,Ke-Da Yu
You-Peng Ding
The chemical modification of biological molecules is a critical regulatory mechanism for controlling molecular functions. Although research has long focused on DNA and proteins, RNA modifications have recently attracted substantial interest...
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults [0.03%]
用于儿童、青少年和年轻成人急性淋巴细胞白血病接受嵌合抗原受体T细胞治疗后早期并发症的西利珠单抗疗法
Víctor Galán-Gómez,Berta González-Martínez,Anna Alonso-Saladrigues et al.
Víctor Galán-Gómez et al.
Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are complications associated with CAR T-cell therapy. Siltuximab directly binds interleukin-6 (IL-6) and may b...
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression [0.03%]
HBG2远端启动子中的一次单碱基治疗性插入重新激活了γ-珠蛋白的表达
Xiuqin Bao,Yuanyi Gao,Xiaoyi Chen et al.
Xiuqin Bao et al.
Background: The reactivation of developmental silenced γ-globin genes (HBG1/2) has shown promise as a therapeutic strategy for improving symptoms of β-hemoglobinopathies. Currently, the focus of therapeutic targets is p...
Lasse Vedel Jørgensen,Emil Birch Christensen,Mike Bogetofte Barnkob et al.
Lasse Vedel Jørgensen et al.
Chimeric antigen receptor (CAR) NK cell therapy has emerged as a promising alternative to CAR T cell therapy, offering significant advantages in terms of safety and versatility. Here we explore the current clinical landscape of CAR NK cells...
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma [0.03%]
乙型肝炎表面抗原：在肝细胞癌中的致癌机制和临床意义
Bingyan Hao,Yachong Liu,Bohan Wang et al.
Bingyan Hao et al.
Liver cancer is the third leading cause of death globally, with hepatitis B virus (HBV) infection being identified as the primary risk factor for its development. The occurrence of HBV-related hepatocellular carcinoma (HCC) is attributed to...
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting [0.03%]
多发性骨髓瘤中对CAR-T细胞治疗抵抗的机制：来自2024年ASH年会的最新更新
Yuhan Hu,Jiangxue Hou,Zhongxing Jiang et al.
Yuhan Hu et al.
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T ...